Endo Health Solutions
The 10-second takeaway
For the quarter ended June 30 (Q2), Endo Health Solutions beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share shrank significantly.
Gross margins increased, operating margins increased, net margins contracted.
Endo Health Solutions tallied revenue of $785.2 million. The 20 analysts polled by S&P Capital IQ predicted net sales of $772.6 million on the same basis. GAAP reported sales were 29% higher than the prior-year quarter's $607.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.27. The 23 earnings estimates compiled by S&P Capital IQ averaged $1.19 per share. GAAP EPS of $0.08 for Q2 were 82% lower than the prior-year quarter's $0.44 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 62.5%, 150 basis points better than the prior-year quarter. Operating margin was 26.9%, 190 basis points better than the prior-year quarter. Net margin was 1.2%, 780 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $823.5 million. On the bottom line, the average EPS estimate is $1.37.
Next year's average estimate for revenue is $3.17 billion. The average EPS estimate is $5.01.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 427 members out of 446 rating the stock outperform, and 19 members rating it underperform. Among 133 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 131 give Endo Health Solutions a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Endo Health Solutions is outperform, with an average price target of $43.55.
- Add Endo Health Solutions to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.